Humberwide Commissioning Policy Statements

These policies are shared by NHS organisations inside the Humber Coast and Vale Health and Care Partnership area.  Click here for the Humber aligned commissioning policy statements, which have been classified in line with national terminology.

NHS Hull CCG policies/policy statements

This page contains details of the decisions about the treatments and medicines provided locally by the NHS.

If you need any of these documents in an alternative format please contact: HULLCCG.contactus@nhs.net

*** IMPORTANT: Hull Clinical Commissioning Group has been dissolved and replaced by the Humber and North Yorkshire Integrated Care Board (ICB) on 1 July 2022. Details of the arrangements for individual funding requests (treatment not routinely commissioned by the NHS) can be found on the ICB website at www.humberandnorthyorkshire.icb.nhs.uk/ifr/ ***

The Integrated Care Board (ICB) has established a clinically and professionally led Group comprised of former CCG experts, which includes GPs representing each local area, to lead the review of all clinical policies. The group aims to prepare commissioning policies in two waves – wave one will be completed by the end of March 2023 and wave two by the end of March 2024. 

Until the review is complete, the ICB has adopted an interim approach to Individual Funding Requests, using commissioning statements aligned to CCG areas as they were on the 30 June 2022 and the Hull ones are set out below.  More information can be found at: www.humberandnorthyorkshire.icb.nhs.uk/ifr ***  

Primary Care Rebate Scheme

Hull CCG Primary Care Rebate Scheme Policy          Download Policy

Hull Clinical Commissioning Group has signed up for the following primary care rebate schemes:

• Beclometasone dipropionate Inhaler (Clenil Modulite)
• ConvaTec Primary Care Dressings
• Edoxaban (Lixiana)
• Fentanyl (Mezolar) Matrix Patch
• Insulin Glulisine (Apidra)
• Isophane Insulin (Insuman)
• Quetiapine (Zaluron XL)
• Quetiapine (Biquelle XL)